---
document_datetime: 2025-12-04 09:37:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/paxlovid-epar-all-authorised-presentations_en.pdf
document_name: paxlovid-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7957024
conversion_datetime: 2025-12-28 18:30:06.939075
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength        | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size            |
|------------------|-------------------|-----------------|-----------------------|---------------------------|-----------------------|----------------------|
| EU/1/22/1625/001 | Paxlovid          | 150 mg + 100 mg | Film-coated tablet    | Oral use                  | blister (OPA/alu/PVC) | 30 (20 + 10) tablets |
| EU/1/22/1625/002 | Paxlovid          | 150 mg + 100 mg | Film-coated tablet    | Oral use                  | blister (OPA/alu/PVC) | 11 (6 + 5) tablets   |
| EU/1/22/1625/003 | Paxlovid          | 150 mg + 100 mg | Film-coated tablet    | Oral use                  | blister (OPA/alu/PVC) | 20 (10 + 10) tablets |